The committed stem and progenitor cells have been recently isolated from various adult tissues, including hematopoietic stem cell, neural stem cell, mesenchymal stem cell and endothelial progenitor cell. These adult stem cells have several advantages as compared with embryonic stem cells as their practical therapeutic application for tissue regeneration.
Introduction
The availability of embryonic stem (ES) cell lines in mammalian species has greatly advanced the field of biological research by enhancing our ability to manipulate the genome and by providing model systems to examine cellular differentiation. ES cells, which are derived from the inner mass of blastocysts or primordial germ cells, can be maintained continuously in an undifferentiated pluripotent state. They have the potential to contribute to a variety of differentiated cell lineages in the fetus, including germ cells. 1, 2 Furthermore, targeted mutations in ES cells have been introduced into the mouse germ line to elucidate target gene function in vivo and create mouse models of human genetic diseases and abnormalities. 3, 4 ES cells have also been used to study the events regulating the differentiation of various cell types and tissues in vitro, for example, into multiple hematopoietic lineages, endothelial cells, neural cells and mesenchymal cell lineages. The transfer of ES-derived cells into fetal and adult mice has demonstrated their functional integration into organs of recipient animals. [5] [6] [7] [8] [9] [10] In 1998, Thomson's group at the University of Wisconsin and Gearhart's group at the Johns Hopkins Hospital isolated human cells with the pluripotent property of ES cells. 11, 12 This exciting achievement opened the way to the clinical application of stem cell therapy: the replacement of diseased or degenerating cell populations, tissues and organs.
Stem cell in adult species
ES cells are not the only candidates for stem cell generation. During embryonic development, the pluripotency of ES cell is narrowed to 'determined stem cells' which give rise to cells of a particular tissue. 13 Thus neural stem cells give rise to cells of the nervous system and hemato- poietic stem cells to blood cells. The determined stem cells differentiate into 'committed progenitor cells', which retain a limited capacity to replicate and phenotypic fate. In the past decade, researchers have defined such committed stem or progenitor cells from various tissues, including bone marrow, peripheral blood, brain, liver and reproductive organs, in both adult animals and humans ( Figure 1 ). While most cells in adult organs are composed of differentiated cells, which express a variety of specific phenotypic genes adapted to each organ's environment, quiescent stem or progenitor cells are maintained locally or in the systemic circulation and are activated by environmental stimuli for physiological and pathological tissue regeneration.
Tissue replacement in the body takes place by two mechanisms. One is the replacement of differentiated cells by newly generated populations derived from residual cycling stem cells. Blood cells are a typical example of this kind of regeneration. Whole hematopoietic lineage cells are derived from a few self-renewal stem cells by regulated differentiation under the influence of appropriate cytokines and/or growth factors. The second mechanism is the self-repair of differentiated functioning cells preserving their proliferative activity. Hepatocytes, endothelial cells, smooth muscle cells, keratinocytes and fibroblasts are considered to possess this ability. Following physiological stimulation or injury, factors secreted from surrounding tissues stimulate cell replication and replacement. In contrast, those cells which are more fully differentiated are limited in terms of their proliferative potential by senescence, and by their inability to incorporate into remote target sites.
Thus, quiescence stem or progenitor cells in most adult tissues are mobilized in response to environmental stimuli when an emergent regenerative process is required, while during a minor event, neighboring differentiated cells are relied upon.
Gene Therapy 
Stem cell therapy
Recently, the regenerative potential of stem cells has been under intense investigation. In vitro, stem and progenitor cells possess the capability of self-renewal and differentiation into organ-specific cell types. In vivo, transplantation of these cells may reconstitute organ systems, as shown in animal models of diseases. [14] [15] [16] [17] [18] In contrast, differentiated cells do not exhibit such characteristics. Human endothelial progenitor cells (EPCs), for example, have been isolated from the peripheral blood of adult individuals, expanded in vitro and committed into an endothelial lineage in culture. 15 The transplantation of human EPCs has been shown to facilitate successful salvage of limb vasculature and perfusion in athymic nude mice with severe hindlimb ischemia, while differentiated endothelial cells (human microvascular endothelial cells, HUMEC) failed to accomplish limb-saving neovascularization. 19 The committed stem and progenitor cells isolated from the adult species have several advantages as compared with ES cell in terms of their possible therapeutic application for tissue regeneration. First, committed stem and progenitor cells can be transplanted autologously without immunologic consequences. As adult stem and progenitor cells are already determined or committed to cell types for targeted organs, they spontaneously differentiate under controlled conditions in vitro into specific lineage cells, and have the ability to reconstitute target organs in vivo. In contrast, ES cells are still under investigation for direct induction of specific cell differentiation for therapeutic application. Furthermore, ethical issues about the isolation and the use of human ES are currently quite controversial.
Thus, while ES cells represent a promising cell source for gene therapy in the future, this review will focus primarily on gene-modified cell therapy using adult stem cells. Modification of organ property/progeny target Genes introduced into stem cells are inherited by their progeny through differentiation cascades. Specifically, expression of the inserted gene may persist through the life of the organ system which is reconstructed by the gene-modified stem cells. Genetically disordered organs, especially in the case of hematopoietic pathology, could be replaced by this strategy following bone marrow transplantation.
Gene-modified stem cell therapy
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Figure 2 Targets of stem cell gene modification for therapeutic regeneration.
Acceleration of regeneration/process target Regeneration of injured tissues is in part or primarily achieved via stem cell expansion and differentiation. Examples include endothelial progenitor cells for neovascularization, neural stem cells for neurogenesis, and hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) for bone marrow reconstruction. Natural reparatory processes are often too impaired from unexpectedly severe injury, basic diseases, or aging to accomplish regeneration. Gene modification of stem cells to supplement mitogens 25 or to deliver inhibitory factors for negative control might accelerate retarded regenerative processes following stem cell proliferation, incorporation, and gene expression in situ.
Expressional organization/systemic target To supply target molecules for therapeutic use, transplantation of genetically modified stem cells might generate expressional tissues or pseudo-organs. The established tissues or organs will continuously express a certain amount of molecules locally or generally for the short or long term by means of vector selection and conditioning. This strategy could represent an alternative approach for therapeutic delivery in lieu of standard drug distribution and uptake.
Gene Therapy
Stem cell gene transfer and associated target disorders
Hematopoietic stem cells A hematopoietic stem cell is a determined multipotent stem cell, which is able to differentiate along a number of pathways and thereby generate erythrocytes, granulocytes, monocytes, mast cells, lymphocytes and megakaryocytes. These stem cells are limited in number, occurring with a frequency of one stem cell per 10 4 bone marrow cells. By virtue of their capacity for self-renewal, stem cells are maintained at homeostatic levels throughout adult life. Due to their low frequency and the difficulties associated with maintaining stem cells in culture, little is known about the regulation of HSC proliferation and differentiation.
While the true phenotype of the human HSC has not been fully characterized, the CD34 +
CD38
− population is known to be enriched for cells with high repopulation capacity and is essential for engraftment in animal models. 14 More recently, KDR expression has been shown to be essential for the CD34 + subset of hematopoietic stem cells. 26 Several organ systems have been evaluated for isolation of HSCs. Bone marrow serves as a source of HSCs as does the peripheral blood, where HSCs circulate, although in much lower frequencies than they are found in bone marrow. To increase the number of circulating HSCs, patients have been treated with cytokines such as granulocyte colony-stimulating factor (G-SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and stem cell factor, all of which are known to mobilize bone marrow-derived progenitors into the peripheral circulation. The relative abundance of HSCs, characterized by their CD34 + CD38 − phenotype makes human umbilical cord blood an ideal source for gene therapy protocols. 27 In addition, highly purified CD34 +
− hematopoietic progenitors have been isolated from human fetal liver. 28 The unique ability of hematopoietic stem cells to engraft in a recipient and establish long-term repopulation of the hematopoietic system makes them ideal targets for gene therapy vectors designed to correct inherited or acquired diseases affecting the hematopoietic and immune systems. Theoretically, many single human gene disorders (eg hemoglobinopathies, immunodeficiencies, lipid storage disorders and platelet glycoprotein deficiencies) which affect the function of mature blood cells of a specific lineage 20 could be treated by the introduction of the defective or missing gene into autologous hematopoietic stem cells. Indeed, gene therapy of hematopoietic cells has already been applied to patients with adenosine deaminase (ADA) deficiency, 29 Gaucher disease, 21 HIV infection 22 and cancer.
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Endothelial progenitor cells Conventionally, physiological (reproduction system) and pathological (ischemia, tumor, wound healing) vascular developments have been considered to be established by sprout formation, ie proliferation of pre-existing differentiated ECs. 30, 31 Transplantation of differentiated ECs, however, reportedly fails to augment impaired neovascularization in severely ischemic tissues. 32 Recently, EPCs have been isolated from peripheral blood and bone marrow, and shown to be incorporated into sites of physiological and pathological neovascularization in vivo. 15, 33, 34 In contrast to differentiated ECs, transplantation of EPCs successfully enhanced vascular development by in situ differentiation and proliferation within ischemic organs. 16 This beneficial property of EPC is attractive for cell therapy as well as gene therapy applications.
As cells already committed to an endothelial lineage, cells isolated at the present time were termed progenitors in our initial report. 15 During embryogenesis, mesodermderived hemangioblasts are common stem cells for both angioblasts (EPCs) and HSCs. 35 Although EPCs and HSCs of adult species express in common certain epitopes (flk-1, tie-2, CD34, Sca-1, c-Kit etc), 36 a bipotent stem cell for both lineages has not been defined. EPCs are so few in number in peripheral blood and bone marrow that mobilization and/or ex vivo expansion will be required for clinical applications. 37, 38 Ex vivo cultured EPCs may be genetically transduced by recombinant adenoviral vectors encoding VEGF, and demonstrate significantly enhanced neovascularization even when 10 times fewer cells were injected. 25 This strategy could be applied to peripheral vascular disease and myocardial ischemia to augment impaired collateral development. Genetic modification of EPCs by genes designed to growth and development of neoplasms will be achieved in situ via incorporation of EPCs into tumor vasculature.
Neural stem cells
Several groups have identified adult neural stem cells (NSCs) that are able to differentiate to neurons, astrocytes and oligodendrocytes. The potential of treating neurodegenerative disorders such as Parkinson's disease or multiple sclerosis reveals a promising therapeutic potential of NSCs. 17, 18 Genetically engineered NSCs have been shown to differentiate selectively into oligodendrocytes, which, after in vitro expansion, were used to remyelinate the vast majority of axons after transplantation in a demyelinated area. 39 Furthermore, recombinant adenoviral vectors can successfully transfect human neural progenitor cells with exogenous genes allowing options of ex vivo gene therapy. 40 In fact, transplantation of NSCs genetically modified to secrete nerve growth factor (NGF) was able to ameliorate the death of striatal projection neurons caused by transient focal ischemia in the adult rat. 41 The clinical potential of genetically modified neural precursors for the treatment of neurodegenerative diseases is promising, but development of successful therapies will depend on better characterization of the origin and differentiation factors affecting NSCs. 42 
Mesenchymal stem cells
Bone marrow stroma provides the microenvironment for hematopoiesis by supporting proliferation and differentiation of hematopoietic stem cells and is also the source of non-hematopoietic, mesenchymal stem cells (MSCs). 43 MSCs share certain characteristics of stem cells, including the capability to differentiate in culture into osteoblasts, chondrocytes, adipocytes, fibroblasts, myoblasts and cardiomyoblasts. 44 Characteristically quiescent and non-cycling with low cell turnover, MSCs have been explored as vehicles for gene therapy based on their ability to engraft in marrow, ie to deliver certain secreted protein to a local site, and to provide progeny for the repopulation of other tissues. Genetic-engineered MSCs have been shown to serve as an effective vehicle for the replacement of genes responsible for deficiencies in circulating proteins. There are, for example, reports of a therapeutic approach for hemophilia B or severe osteogenesis imperfecta by transfecting human MSCs with a gene for factor IX 45, 46 or for type I collagen. 47 The ability to induce MSC differentiation in specific tissues by using gene transfer techniques reveals the therapeutic possibility of treating a variety of human diseases. This potential has been used for example by adenovirus-mediated bone morphogenetic protein-2 gene transfer into MSCs, which could potentially direct differentiation into cells having an osteoblast phenotype in vitro and bone formation in vivo. 48 While cultured murine stromal cells have been shown to engraft into murine recipients following intravenous infusion, 49 engraftment of transplanted stromal cells in humans remains to be documented.
Gene transfer vectors
A number of requirements for gene transfer to stem cells determine the choice of the appropriate vector or gene transfer vehicle. Sufficient integration of the transferred gene into the host genome of the target stem cell is necessary to achieve subsequent transmission to all progeny cells and to obtain durable effects. Other applicationssuch as targeting regenerative processes -require only temporary cell engineering.
Retroviral vectors
Most reported attempts to transduce HSCs for gene therapy protocol have used retroviral vectors, such as the murine leukemia virus (MLV). These vectors, which can accept up to 8 kilobases (kb) of exogenous DNA, require cell division in order to integrate in their genome. 50 Therefore, most ex vivo retroviral gene transfer protocols include the addition of a variety of stimulatory cytokines to induce cycling in the HSC population before sequential addition of vector-containing supernatants. Current investigations differ in the number of cycles of infection and the length of exposure of stem cells to retroviral vectors, the liability being progressive differentiation and the loss of repopulation ability. However, progress in the field of genetic transfer or modification into human longterm repopulating stem cells mediated by retroviral vectors has been blocked by the fact that levels of transfection are too low for any likely therapeutical benefit. 51, 52 Several reports have demonstrated that an important reason for the low levels of transduction might involve certain incompatible features of the vectors used and the stem cells that they target.
Lentiviral vectors
There is increasing evidence that lentivirus-based systems might be ideal vectors for the transduction of human HSCs. Lentiviruses constitute another retrovirus subgroup and include the human immunodeficiency virus (HIV) type 1 envelope. While retrovirus systems are inefficient at transducing nondividing or slowly dividing cells, lentivirus-based vectors when pseudotyped with vesicular stomatitis virus glycoprotein G (VSV-G) 53 or gibbon ape leukemia virus (GALV) 54 have the capability to mediate genome integration into nondividing human HSCs. 55 Pseudotyping implicates incorporation of protein envelopes from other viruses into the HIV-1-based vectors and is necessary for these vectors, because they naturally infect only CD4 + T lymphocytes and macrophagelineage cells. There is evidence that lentiviral vectors could transduce more primitive, quiescent progenitors than MLV with stable transgene integration 60 days after infection. 56 In comparison with retrovirus vectors, lentiviral systems allow the immediate transduction after cell sorting without any prior expansion or growth factor stimulation with only short exposure times. Transduction efficiencies of around 60% HSCs in cord blood have been reported. 14 Further investigations analyzing gene transfer into longterm repopulating cells of large animals and the use of improved vector systems will be needed to establish the superiority of lentiviral vectors.
Adeno-associated viral vectors
Recombinant adenovirus-associated viruses (rAAV), which can take up to 4.8 kb of exogenous DNA are also being explored as potential vectors for introduction of genes into HSCs. 57 This encapsulated single-stranded, nonpathogenic DNA parvovirus has been shown to infect primate hematopoietic progenitor cells with reasonable efficiency; even so its use involves coinfection with a helper virus such as adenovirus or herpes simplex virus. Use of rAAV will require the development of optimized cotransfection and helper plasmid strategies for productive infection. 58 Gene Therapy
Adenovirus vectors
Adenovirus vectors have been successfully used for transient gene expression in many systems, although standard adenovirus does not usually allowed stable integration. 59 It does not require cycling of the target cell for gene transfer, appears to utilize an integrin-dependent mechanism for cell entry, and has evolved an efficient mechanism for gene delivery from the cell surface to the nucleus. It is utilized to achieve transient genetic engineering of stem cells especially for acceleration of regenerative responses, such as cytokine or growth factor gene transduction of EPCs for angiogenesis, MSCs for formation of bone, cartilage or muscle development, and NSCs for neurogenesis.
Factors limiting gene transfer into stem cells
One important issue which potentially limits gene transfer of retroviral vectors into HSCs is the quiescent nature and reduced receptor expression of primate HSCs. Lentivirus-based vectors overcome this limitation and may therefore represent an alternative to retroviruses. While rAAVs achieve sufficient short-term transduction, longterm expression with this vector system is reported to be limited to less than 6 months.
Successful gene therapy applications require optimized strategies to increase gene transfer efficiency and expansion in balance with maintenance of the immature state of HSCs. Today, important experimental variables include multiplicity of infection, length of time or viral incubation, medium used for viral incubation, the viral construct (including promoter and gene), and the source of the stem cells. The determination of factors controlling HSC proliferation, differentiation and expression of the transgene after each cycle of transduction are important issues which are currently under investigation.
One final issue concerns the selection of successfully transduced stem cells. Ex vivo selection involves cell surface antigen expression and autofluorescent (GFP) marking while an in vivo selection method is based on separating transduced cells by conferring drug resistance (dihydrofolate reductase) or by selective amplifier genes (chimeric receptor). 60, 61 The in vivo selection by drug treatment after transplant also offers the possibility to selectively increase the number of primitive and mature transduced stem cells. 62 
